Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Arrouss, Issam ^a   Nemati, Fariba ^b   Roncal, Fernando ^c   Wislez, Marie ^d   Dorgham, Karim ^a   Vallerand, David ^b   Rabbe, Nathalie ^d   Karboul, Narjesse ^b   Carlotti, Françoise ^e   Bravo, Jeronimo ^f   Mazier, Dominique ^a   Decaudin, Didier ^b   Rebollo, Angelita ^a  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HÔPITAL TENON   (France)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; DPT C9H PEPTIDE; PEPTIDE DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; CYTOCHROME C; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BREAST NEOPLASMS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; SECRETION (PROCESS); SPECIES DIFFERENCE; TUMOR CELL LINE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CASPASE 9; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CYTOCHROMES C; DRUG DESIGN; FEMALE; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN PHOSPHATASE 2; SPECIES SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876543948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060816     Document Type: Article

References (50)

1. Lyon MA, Ducruet AP, Wipf P, Lazo JS, (2002) Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov 1: 961-976.
2. Ducret F, Turc-Baron C, Pointet P, Vernin G, Skowron O, et al. (2005) [Renin-secreting tumour: about a new diagnosed case during pregnancy]. Nephrol Ther 1: 52-61.
3. Lazar DF, Saltiel AR, (2006) Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov 5: 333-342.
4. Tonks NK, (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7: 833-846.
5. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
6. Li YM, Casida JE, (1992) Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci U S A 89: 11867-11870.
7. Honkanen RE, (1993) Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330: 283-286.
8. Walsh AH, Cheng A, Honkanen RE, (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416: 230-234.
9. Medyouf H, Alcalde H, Berthier C, Guillemin MC, dos Santos NR, et al. (2007) Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 13: 736-741.
10. Martinez-Martinez S, Redondo JM, (2004) Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem 11: 997-1007.
11. Ayllon V, Martinez AC, Garcia A, Cayla X, Rebollo A, (2000) Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis. Embo J 19: 2237-2246.
12. Dessauge F, Cayla X, Albar JP, Fleischer A, Ghadiri A, et al. (2006) Identification of PP1alpha as a caspase-9 regulator in IL-2 deprivation-induced apoptosis. J Immunol 177: 2441-2451.
13. Signorile A, Sardanelli AM, Nuzzi R, Papa S, (2002) Serine (threonine) phosphatase(s) acting on cAMP-dependent phosphoproteins in mammalian mitochondria. FEBS Lett 512: 91-94.
14. Rubin E, Mittnacht S, Villa-Moruzzi E, Ludlow JW, (2001) Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1. Oncogene 20: 3776-3785.
15. Edwards MJ, Thomas RC, (2000) Protein phosphatase type 1-dependent dephosphorylation of the retinoblastoma tumor suppressor protein in ultraviolet-irradiated human skin and keratinocytes. J Invest Dermatol 115: 88-94.
16. Ayllon V, Cayla X, Garcia A, Fleischer A, Rebollo A, (2002) The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad. Eur J Immunol 32: 1847-1855.
17. Ayllon V, Cayla X, Garcia A, Roncal F, Fernandez R, et al. (2001) Bcl-2 targets protein phosphatase 1 alpha to Bad. J Immunol 166: 7345-7352.
18. Ray RM, Bhattacharya S, Johnson LR, (2005) Protein phosphatase 2A regulates apoptosis in intestinal epithelial cells. J Biol Chem 280: 31091-31100.
19. Singh K, Communal C, Colucci WS, (2000) Inhibition of protein phosphatase 1 induces apoptosis in neonatal rat cardiac myocytes: role of adrenergic receptor stimulation. Basic Res Cardiol 95: 389-396.
20. Kang HS, Choi I, (2001) Protein phosphatase 2A modulates the proliferation of human multiple myeloma cells via regulation of the production of reactive oxygen intermediates and anti-apoptotic factors. Cell Immunol 213: 34-44.
21. Jan G, Delorme V, David V, Revenu C, Rebollo A, et al. (2007) The toxofilin-actin-PP2C complex of Toxoplasma: identification of interacting domains. Biochem J 401: 711-719.
22. Bitler BG, Schroeder JA, (2010) Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov 5: 99-108.
23. Prochiantz A, (2000) [Messenger proteins]. J Soc Biol 194: 119-123.
24. Guergnon J, Dessauge F, Dominguez V, Viallet J, Bonnefoy S, et al. (2006) Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol 69: 1115-1124.
25. Guergnon J, Dessauge F, Traincard F, Cayla X, Rebollo A, et al. (2006) A PKA survival pathway inhibited by DPT-PKI, a new specific cell permeable PKA inhibitor, is induced by T. annulata in parasitized B-lymphocytes. Apoptosis 11: 1263-1273.
26. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, et al. (2006) High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66: 4198-4207.
27. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998.
28. de Plater L, Lauge A, Guyader C, Poupon MF, Assayag F, et al. (2010) Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 103: 1192-1200.
29. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, et al. (2010) Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 16: 2352-2362.
30. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, et al. (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7: 3265-3274.
31. Dorgham K, Dogan I, Bitton N, Parizot C, Cardona V, et al. (2005) Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. AIDS Res Hum Retroviruses 21: 82-92.
32. Dorgham K, Ghadiri A, Hermand P, Rodero M, Poupel L, et al. (2009) An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 86: 903-911.
33. Guy CT, Cardiff RD, Muller WJ, (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
34. Yamano H, Ishii K, Yanagida M, (1994) Phosphorylation of dis2 protein phosphatase at the C-terminal cdc2 consensus and its potential role in cell cycle regulation. Embo J 13: 5310-5318.
35. Obeid M, (2009) Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin-inducer peptides. Mol Cancer Ther 8: 2693-2707.
36. Kroemer G, Pouyssegur J, (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
37. Massodi I, Bidwell GL 3rd, Davis A, Tausend A, Credit K, et al (2009) Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis 26: 251-260.
38. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, et al. (2003) Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci U S A 100: 11273-11278.
39. Tan M, Lan KH, Yao J, Lu CH, Sun M, et al. (2006) Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66: 3764-3772.
40. Johansson HJ, Andaloussi SE, Langel U, (2009) Mimicry of protein function with cell-penetrating peptides. Methods Mol Biol 683: 233-247.
41. Johnson RM, Harrison SD, Maclean D, (2009) Therapeutic applications of cell-penetrating peptides. Methods Mol Biol 683: 535-551.
42. Jones S, Howl J, (2009) Applications of cell-penetrating peptides as signal transduction modulators for the selective induction of apoptosis. Methods Mol Biol 683: 291-303.
43. Tappan E, Chamberlin AR, (2008) Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. Chem Biol 15: 167-174.
44. Janssens V, Goris J, (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439.
45. Wong LL, Zhang D, Chang CF, Koay ES, (2010) Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. Exp Cell Res 316: 3387-3396.
46. Liu S, Dontu G, Wicha MS, (2005) Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7: 86-95.
47. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, et al. (2005) Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. J Biol Chem 280: 29519-29524.
48. Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, et al. (2009) Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 28: 3837-3846.
49. Kim SS, Cao L, Baek HJ, Lim SC, Li C, et al. (2009) Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1. Cancer Res 69: 9291-9300.
50. Modak C, Bryant P, (2008) Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines. Biochem Biophys Res Commun 368: 801-807.